The purpose of this study is to determine the safety and tolerability of acarbose in combination of immunotherapy based standard of care therapy in advanced renal cell carcinoma patients.

Start Date31 Dec 2025

Sponsor / Collaborator

The University of Alabama at Birmingham

NCT07074379

/ Not yet recruitingNot ApplicableIIT

Endotherapy and/or Extracorporeal Shockwave Lithotripsy Versus Conservative Treatment in Painless Chronic Pancreatitis

Chronic pancreatitis (CP) is caused by factors such as genetics and the environment, leading to the destruction of pancreatic tissue, infiltration of inflammatory cells, and progressive fibrosis of the pancreas. As the disease progresses, pancreatic tissue is damaged, resulting in impaired endocrine and exocrine functions, manifesting as symptoms like steatorrhea and diabetes. Pain associated with chronic pancreatitis (PACP) is the most common symptom in CP patients. Approximately 75% of patients initially present with abdominal pain, and previous studies have shown that PACP can occur in 85-97% of CP patients. However, there is a type of pancreatitis where patients do not experience abdominal pain and typically seek medical attention due to routine check-ups or symptoms of pancreatic endocrine and exocrine dysfunction; this particular type of pancreatitis is known as painless CP. A meta-analysis showed that painless CP accounts for about 12% of all CP patients.
In patients with CP, continuous pancreatic damage leads to the destruction of pancreatic tissue, subsequently causing insufficiency in both exocrine and endocrine functions. "Painless" does not equate to "harmless"; patients with painless CP often present with severe symptoms of pancreatic exocrine and endocrine dysfunction at the time of diagnosis. These findings underscore the importance of early identification and active management of patients with painless CP.
Whether active endoscopic intervention is needed for painless CP remains a matter of debate. The European Society of Gastrointestinal Endoscopy (ESGE) suggests endoscopic therapy and/or extracorporeal shockwave lithotripsy (ESWL) as the first-line therapy for painful uncomplicated chronic pancreatitis (CP) with an obstructed main pancreatic duct (MPD) in the head/ body of the pancreas; however, due to the unclear potential benefits (preservation of pancreatic function) of endoscopic and/or ESWL treatment for painless CP, it is not recommended for patients without pain, although the evidence is of low quality.
Although there is currently no consensus on whether endoscopic treatment can protect the pancreatic function of patients with painless chronic pancreatitis, preliminary evidence suggests that endoscopic treatment may have a positive impact on pancreatic atrophy and dysfunction in patients with painless CP. In a retrospective study by Ikeura et al., which included 268 patients with CP and painless pancreatic duct stones, it was found that endoscopic treatment and complete clearance of stones in patients with painless pancreatic duct stones helped maintain the volume of the pancreatic parenchyma.
Although preliminary research suggests that endoscopic treatment may protect pancreatic function in patients with painless CP, it could also trigger pain. A study by Ikeura et al. found that painless CP patients who underwent endoscopic treatment but did not have complete clearance of pancreatic duct stones were at a significantly higher risk of developing pain. This indicates that incomplete endoscopic treatment might lead patients from a painless state to one of pain. However, a study by Amodio et al. suggests that the likelihood of painless CP patients experiencing pain in the short term is low, implying that conservative treatment might be more appropriate.
Current research on the clinical characteristics of painless CP and its response to treatment is relatively limited, necessitating further clinical studies to clarify the impact of ERCP and/or ESWL on these patients. We plan to conduct a randomized controlled trial to assess whether these minimally invasive interventions can improve clinical outcomes for patients with painless CP

Start Date21 Jul 2025

Sponsor / Collaborator

Changhai Hospital of Shanghai

CTR20244876

/ CompletedNot Applicable

阿卡波糖片健康人体生物等效性试验

[Translation] Bioequivalence study of acarbose tablets in healthy volunteers

主要研究目的研究受试制剂阿卡波糖片（规格：0.1g，生产厂家：北京双鹭药业股份有限公司）和参比制剂阿卡波糖片（商品名：拜唐苹®，规格：0.1g，持证商为拜耳医药保健有限公司）在健康受试者空腹状态下单剂量给药时的药效动力学特征，评价两制剂的人体生物等效性。次要研究目的观察受试制剂阿卡波糖片和参比制剂拜唐苹®在健康受试者中的安全性。

[Translation]

The main purpose of the study is to study the pharmacodynamic characteristics of the test preparation acarbose tablets (specification: 0.1g, manufacturer: Beijing Shuanglu Pharmaceutical Co., Ltd.) and the reference preparation acarbose tablets (trade name: Baytangping®, specification: 0.1g, licensee is Bayer Pharmaceuticals Co., Ltd.) when administered as a single dose to healthy subjects in the fasting state, and to evaluate the bioequivalence of the two preparations in humans. The secondary purpose of the study is to observe the safety of the test preparation acarbose tablets and the reference preparation Baytangping® in healthy subjects.

Start Date10 Feb 2025

Sponsor / Collaborator

Beijing SL Pharmaceutical Co., Ltd.

100 Clinical Results associated with Acarbose

100 Translational Medicine associated with Acarbose

100 Patents (Medical) associated with Acarbose

5,891

Literatures (Medical) associated with Acarbose

31 Dec 2025·JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

Profiling and cheminformatics bioprospection of curcurbitacin I and momordin Ic from Momordica balsamina on α-amylase and α-glucosidase

Article

Author: Jaichand, Viruska ; Mohanlall, Viresh ; Lanrewaju, Adedayo Ayodeji ; Sabiu, Saheed ; Baijnath, Himansu

Momordica spp. has been traditionally used to manage type 2 diabetes mellitus, but the mechanisms and metabolites remain unclear. This study evaluated the inhibitory potential of Momordica balsamina extracts on α-amylase and α-glucosidase in vitro, identifying cucurbitacin I and momordin Ic via high-performance liquid chromatography-photo diode array, and their inhibitory potential in silico. Ethyl acetate seed extract (14.46 µg/ml) and hexane fruit flesh extract (16.79 µg/ml) exhibited lower IC₅₀ values against α-amylase and α-glucosidase, respectively, compared to acarbose (reference standard). Comparatively, momordin Ic concentrations (36.57-605.98 µg/ml) were higher than cucurbitacin I (17.08-44.34 µg/ml). A 140 ns simulation showed that cucurbitacin I (-63.06 kcal/mol) and momordin Ic (-66.53 kcal/mol) exhibited stronger binding to α-amylase than acarbose (-36.46 kcal/mol), whereas cucurbitacin I (-38.08 kcal/mol) and momordin Ic (-54.87 kcal/mol) displayed weaker binding to α-glucosidase, relative to acarbose (-63.73 kcal/mol). Generally, momordin Ic demonstrated better thermodynamic properties, hence further in vitro and in vivo studies are needed to validate their antidiabetic potential.

31 Dec 2025·JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

Activity guided discovery of dual inhibitors of α-glucosidase and β-glucuronidase from the leaves of Millettia pachycarpa Benth

Article

Author: Tan, Shaoqian ; Long, Jing ; Zhu, Liangliang ; Xu, Huanran ; He, Yanxi ; You, Jingcan ; Lei, Hui ; Lü, Muhan ; Xiao, Ling ; Xiong, Xia ; Liang, Sicheng ; Qi, Xiaoyi ; Deng, Mingming

Type 2 diabetes mellitus (T2DM) and cancers are two globally prevalent diseases which can increase the incidence of each other. Intestinal α-glucosidase and β-glucuronidase are key targets for glycaemic control and chemotherapy detoxification, respectively. This study first found that the leaf methanol extract of Millettia pachycarpa displayed dual inhibition to the two enzymes. The dually active constituents were then isolated and identified as two prenylated isoflavones of 6,8-diprenylorobol and 6,8-diprenylgenistein. Diprenylorobol exhibits competitive inhibition to both the two enzymes with K_i values of 21.6 μM (α-glucosidase) and 1.41 μM (β-glucuronidase). Diprenylgenistein is an uncompetitive inhibitor of α-glucosidase (K_i = 11.4 μM) but a competitive inhibitor of β-glucuronidase (K_i = 1.69 μM). Molecular docking studies showed that both the two isoflavones tightly bind into the active pockets via various hydrogen bonds and hydrophobic interactions. In summary, the current study identifies two promising dual inhibitors of α-glucosidase and β-glucuronidase from the leaves of Millettia pachycarpa.

31 Dec 2025·Artificial Cells Nanomedicine and Biotechnology

Seaweed extract as a sustainable resource for Au nanoparticle synthesis and its biological and environmental applications

Article

Author: Shin, Han-Seung ; Patra, Jayanta Kumar ; Das, Gitishree

In this study, gold nanoparticles (AuNPs) were bio-fabricated using the water extract of marine brown seaweed Hizikia fusiformis (Hfs), commonly eaten as food in Southeast Asia, Korea, China, and Japan, and in other parts of the world. This process offers massive potential for the manufacture of new-generation nanomaterials utilizing sustainable seaweed components and explores its biological (tyrosinase, antidiabetic, antioxidant) and environmental (photocatalytic degradation of toxic industrial dyes) applications. Different spectroscopic approaches were employed to characterize and confirm the fabrication of Hfs-AuNPs. UV-Vis spectroscopy displayed the Hfs-AuNP's surface plasmon resonance at 534 nm. The XRD result revealed the crystalline nature of the nanoparticle. According to FT-IR analysis, various phytoconstituents like polyphenols and polysaccharides from the Hfs extract contributed to the reduction and stabilization of Hfs-AuNPs. Hfs-AuNPs displayed a spherical form with a zeta potential of -18.6 mV. Notably, Hfs-AuNPs exhibited encouraging tyrosinase inhibition (31.74 % inhibition while kojic acid showed 52.40 % inhibition at 100 µg/ml), antidiabetic effect (56.38 % α-amylase activity while acarbose exhibited 61.19 % activity at 100 µg/ml), and antioxidant properties (82.89 % of DPPH scavenging while 60.04 % scavenging by BHT and 63.73 SOD effect while 61.77 % scavenging by BHT at 100 µg/ml). Besides, Hfs-AuNPs also displayed positive photocatalytic degradation of toxic industrial dyes like methylene blue (29.20 % degradation at 5 h) and methyl orange (21.26 % degradation at 3 h). The above eco-friendly, cost-effective, and sustainable synthesis method can be explored further for large-scale production and future substantial applications in therapeutic and industrial needs.

News (Medical) associated with Acarbose

23 Oct 2023

·synapse.patsnap.com

Advances in Clinical Research on Amylase Inhibitor

Amylase is an essential enzyme found in the human body that plays a crucial role in the digestion of carbohydrates. Produced primarily in the salivary glands and pancreas, amylase breaks down complex starch molecules into simpler sugars like glucose, maltose, and dextrin. This process begins in the mouth, where salivary amylase initiates the breakdown of starches into smaller fragments. Once in the stomach, the enzyme continues its action until it reaches the small intestine, where pancreatic amylase takes over to complete the digestion process. Without amylase, the body would struggle to efficiently convert carbohydrates into usable energy, leading to potential digestive issues and nutrient deficiencies. Amylase Competitive LandscapeAccording to Patsnap Synapse, as of 27 Sep 2023, there are a total of 5 amylase drugs worldwide, from 6 organizations, covering 7 indications, and conducting 1 clinical trials. 👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs , indications, organizations, clinical trials, clinical results, and drug patents related to this target. Based on the analysis of the provided data, the current competitive landscape of target amylase indicates that companies like Anagram Therapeutics, Inc. and Propanc Biopharma, Inc. are growing rapidly in their R&D efforts. Drugs targeting amylase have been approved for indications such as Exocrine Pancreatic Insufficiency, Neoplasms, Ovarian Cancer, Solid Tumors, Pancreatic Cancer, Malabsorption Syndromes, and Gastrointestinal Diseases. Enzyme-based drugs and small molecule drugs are progressing rapidly, indicating potential competition around innovative drugs. The countries/locations with significant development in target amylase include the United States, European Union, Australia, Spain, France, Denmark, and Belgium. However, the progress in China cannot be determined based on the provided data. Overall, the target amylase market shows promising growth potential with active R&D efforts and a diverse range of indications and drug types. Key drug: AcarboseAcarbose is a small molecule drug that falls under the therapeutic areas of endocrinology and metabolic disease. It is primarily used for the treatment of diabetes mellitus, specifically type 2 diabetes. The drug targets several enzymes including alpha-amylase, GANC, MGAM, and α-glucosidase. 👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug. The originator organization of Acarbose is Bayer AG, a well-known pharmaceutical company. The drug has reached the highest phase of approval globally, indicating its successful development and regulatory progress. Acarbose received its first approval in the United States in September 1995, making it available to patients in that country. One notable aspect of Acarbose is its regulation status, which is classified as priority review. This suggests that the drug has undergone an expedited evaluation process by regulatory authorities, possibly due to its potential benefits and urgency in addressing the medical needs of patients with type 2 diabetes. Acarbose's mechanism of action involves inhibiting the enzymes targeted, which play a role in the digestion and absorption of carbohydrates. By inhibiting these enzymes, Acarbose helps to slow down the breakdown of complex carbohydrates into simple sugars, thereby reducing the postprandial rise in blood glucose levels. This mechanism makes Acarbose a valuable treatment option for individuals with type 2 diabetes, as it helps to control their blood sugar levels. In summary, Acarbose is a small molecule drug developed by Bayer AG for the treatment of type 2 diabetes. It targets multiple enzymes involved in carbohydrate digestion and absorption, and its regulatory status as a priority review drug highlights its potential significance in managing this metabolic disease. Acarbose received its first approval in the United States in 1995 and has since been approved in other countries, including China. Its successful development and regulatory progress make it a valuable addition to the pharmaceutical industry's arsenal in combating diabetes mellitus.

17 Jun 2022

·www.prnewswire.com

Generic Pharmaceuticals Global Markets Report 2022-2026 & 2031: Biosimilar; Simple Generic and Super Generic

DUBLIN, June 17, 2022 /PRNewswire/ -- The "Generic Pharmaceuticals Global Market Report 2022: By Therapy, By Distribution, By Type, By Drug" report has been added to ResearchAndMarkets.com's offering. The global generic pharmaceuticals market is expected to grow from $302.39 billion in 2021 to $332.43 billion in 2022 at a compound annual growth rate (CAGR) of 9.9%. The market is expected to reach $426.30 billion in 2026 at a CAGR of 6.4%. The generic pharmaceuticals market consists of sales of generic pharmaceuticals. A generic medicine is a medication designed to be identical as branded drugs marketed by private companies in dosage form, strength, safety, route of administration, performance characteristics, quality, and intended use. Generic drugs work in the same way as branded drugs in terms of clinical benefits. Generic drugs are manufactured after the expiration of the exclusive rights or patent of the branded drugs. For example, some of the generic drugs in the generic pharmaceuticals market include metformin, metoprolol, acarbose, acebutolol, aztreonam and many more. The main types of generic pharmaceuticals are biosimilar; simple generic and super generic. A biosimilar is a biological product that is very similar to a reference biologic and has no clinically significant differences in terms of safety, purity, or potency. The drugs are delivered through oral, injectables, dermal/topical and inhaler that are used for various therapies such as CNS, cardiovascular, dermatology, genitourinary/hormonal, respiratory, rheumatology, diabetes and oncology. The various distribution channel involved are hospital pharmacies, retail pharmacies and online pharmacies. North America was the largest region in the generic pharmaceuticals market in 2021. Middle East is expected to be the largest growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The rising incidence of chronic diseases is one of the major drivers of the generic pharmaceuticals market. As more individuals are diagnosed with chronic diseases, they look for more medicines for the treatment. Branded drugs come at a premium price, while generic drugs are available at a lower cost having the same chemical composition of branded drugs. The low cost and same chemical composition and strength of generic drugs make a patient buy generic drugs instead of branded drugs. If it is a chronic disease, the treatment goes for a longer period of time and hence, the sales of generic drugs also increase. For instance, according to the WHO (World Health Organization), over the next 10 years, the deaths due to chronic disease is projected to increase by 17%. Also, in 2020, almost 3-quarters of all deaths in the world is due to chronic diseases. The lack of awareness about generic drugs is one of the restraints on the generic pharmaceuticals market. The high marketing and advertisement of branded drugs overshadow the availability of generic drugs which are substitute for expensive branded drugs. Thus, consumers opt branded drugs despite the fact that the generic drugs carry the same chemical formulation as their counter branded drugs. According to an article published on CVS HEALTH, many doctors and pharmacists preferred to offer branded drugs to their patients over generic drugs. This prevents the patients to go for generic drugs as they develop a preconceived notion of generic drugs not being at par with branded drugs. For example, according to a research conducted by Sahana K Hebbar, on International Journal of Basic & Clinical Pharmacology, out of 100 patients and 50 non-medical staff, 95% of the patients and 60% of the non-medical staff didn't know about generic drugs. Thus, lack of awareness about the availability of generic drugs hamper the generic pharmaceuticals market. 3D printing technology has the ability to transform the manufacturing of drugs in the generic pharmaceuticals market. 3D printed pharmaceuticals help in improve R&D productivity and deliver new benefits to patients. 3D printing allows the manufacturer to produce drugs with customized size, shape, and texture which is not possible in traditional manufacturing of generic drugs. 3D printing can help the manufacturer to make generic drugs that have different release dates, appearances and taste. For example, GlaxoSmithKline (GSK) completed a study where ultraviolet (UV) and 3D printing were used to manufacture tablets to treat Parkinson's disease. Martin Wallace, director of GSK Technology, said that GSK is investing in 3D printing advantages to manufacture pills and tablets. Also, Aprecia pharmaceutical company launched 'ZipDose' technology which manufactures 3D printed drugs. The drug manufacturers must comply with the CGMP (Current Good Manufacturing Practice) regulations that come under the US Food and Drug Administration (FDA) which includes generic pharmaceuticals. The CGMP regulations require manufacturers to maintain a minimum quality standard for the methods, controls, and facilities used in manufacturing, packaging, and processing of drug product. The part- 99 of chapter 1 under title 21-Food And Drugs of CFR (Code of Federal Regulations) contains subparts from A to H. The whole part-99 describes the guidelines that need to be followed by drug manufacturers regarding the dissemination of information on human drugs, including biologics, and devices. The guidelines concern with the safety, effectiveness, or benefit of use that is not included in the approved labelling for a drug or device approved by the Food and Drug Administration for marketing. The guidelines regulate the information regarding the drugs that should be delivered to the health care practitioner, pharmacy benefit manager, health insurance issuer, group health plan, or federal or state government agency. Generic Pharmaceuticals Market Competitive Landscape And Company Profiles Teva Pharmaceuticals Mylan NV Sandoz International GmbH Hospira (Pfizer inc.) Sun Pharmaceutical Lupin Limited Endo International plc. Dr Reddy's Laboratories Apotex Holdings Fresenius Kabi Ag Aurbindo Pharma Aspen Pharmacare Sanofi Cipla Hikma Pharmaceuticals Stada Arzneimittel Krka Group Nichi-Iko Pharmaceutical Valeant Zydus Cadila Merck & Co. Mitsubishi Tanabe Pharma Momenta Pharmaceuticals Nexus Pharmaceuticals Novo Nordisk Ranbaxy Laboratories Ltd. Sawai Pharmaceuticals Novartis AG Pfizer Johnson & Johnson Services Key Topics Covered: 1. Executive Summary 2. Generic Pharmaceuticals Market Characteristics 3. Generic Pharmaceuticals Market Trends And Strategies 4. Impact Of COVID-19 On Generic Pharmaceuticals 5. Generic Pharmaceuticals Market Size And Growth 5.1. Global Generic Pharmaceuticals Historic Market, 2016-2021, $ Billion 5.1.1. Drivers Of The Market 5.1.2. Restraints On The Market 5.2. Global Generic Pharmaceuticals Forecast Market, 2021-2026F, 2031F, $ Billion 5.2.1. Drivers Of The Market 5.2.2. Restraints On the Market 6. Generic Pharmaceuticals Market Segmentation 6.1. Global Generic Pharmaceuticals Market, Segmentation By Therapy, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion CNS Cardiovascular Dermatology Genitourinary/Hormonal Respiratory Rheumatology Diabetes Oncology 6.2. Global Generic Pharmaceuticals Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion Hospital Pharmacies Retail Pharmacies Online Pharmacies 6.3. Global Generic Pharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion Biosimilar Simple Generic Super Generic 6.4. Global Generic Pharmaceuticals Market, Segmentation By Drug Delivery, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion Oral Injectables Dermal/Topical Inhaler 7. Generic Pharmaceuticals Market Regional And Country Analysis 7.1. Global Generic Pharmaceuticals Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion 7.2. Global Generic Pharmaceuticals Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Generic DrugBiosimilar

26 Aug 2021

·endpts.com

BioDuro-Sundia plants its flag at former Par manufacturing site in CA

A former Par Pharma site in Irvine, CA, will now have a new tenant. BioDuro-Sundia will acquire a 40,000-square-foot oral solid dose manufacturing site in Irvine, the company announced Monday. The site will allow the company to scale up and cater to companies that need larger-scale production, Kent Payne, the president of development and manufacturing, said in a press release. The new site should be operational by the start of 2022. It will be able to produce 1 billion tablets and capsules a year, the company said. “BioDuro-Sundia is a pioneer in enhancing bioavailability, with 25 years of experience applying stabilized amorphous solid dispersion technology to poorly soluble drug product candidates,” he said. “Our clients have requested our support to provide commercial scale manufacturing to save time and maximize success, and it is a pleasure to take this next step with them.” BioDuro-Sundia is a CDMO with 2,000 employees in 10 sites across the country, including China and the US. The company specializes in small- and large-molecule discovery, IND submission support and the scaling of batches. It bills itself as a one-stop shop for its clients. The site is located at 72 Fairbanks in Irvine and was previously used by Par Pharmaceuticals. They acquired the site from Anchen Pharmaceuticals back in 2011, when they acquired the company. In 2020, BioDuro invested in a 150,000-square-foot R&D site in Wuxi City, China, and says that the integrated system can help save time and produce a better quality drug. In April, the company invested in adding a cGMP manufacturing site at the facility. That location handles oral dosage tablets and capsules. That added to its already-existing site in San Diego. Among the drugs manufactured by the company is Gliclazide, a sustained release tablet to treat diabetes from Tianjin Jun’an Bio. The drug is often used with metformin tablets, acarbose tablets or pioglitazone.

100 Deals associated with Acarbose

External Link

KEGG	Wiki	ATC	Drug Bank
D00216	Acarbose	A10BF01	DB00284

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Germany	-	01 Jan 1990

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glucose Intolerance	Phase 3	Spain	Bayer AG	01 Aug 2000
Hyperglycemia	Phase 1	China	Shanghai Shyndec Pharmaceutical Co., Ltd.	08 Dec 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01490918 (CTgov)	Phase 4	Diabetes Mellitus, Type 2	165	Placebo acarbose (Acarbose Placebo, Metformin, Sitagliptin)	lplegcwigl(zpbqhcxtmi) = amudovyoob paqsghbfoi (zysraonovy, qqpagptanv - ltsnsddfvs) View more	-	17 Aug 2020
				Acarbose (Sitagliptin, Metformin, Acarbose)	lplegcwigl(zpbqhcxtmi) = tozjmnjkvh paqsghbfoi (zysraonovy, tvbzzbhmdh - zjfrfgfyqu) View more
NCT00829660 (ACE, Pubmed \| Diabetes Care)	Phase 4	Coronary Artery Disease	6,526	Acarbose	ltmmljfplf(uvdaktugps) = qxtknlvozs ybdburgngg (jvqtzcsuay ) View more	Positive	08 Jul 2020
				Placebo	ltmmljfplf(uvdaktugps) = fsbbssxwwg ybdburgngg (jvqtzcsuay ) View more
NCT01181674 (REMIT Pilot, CTgov)	Phase 4	Diabetes Mellitus, Type 2	83	insulin glargine+metformin+acarbose (Group 1 (Short))	awweftzwiw = onjiedlmpo nkpkyvinrt (szukvbqucy, uwdybqtozc - lwhsssjcvi) View more	-	21 May 2020
				insulin glargine+metformin+acarbose (Group 2 (Long))	mrdwnmtpjt = aylulsoazb amiprzkzmi (fyfdenzipa, zlawrmdjow - poqafysimi) View more
NCT02865499 (CTgov)	Phase 2	disorder of aging	8	acarbose	rvgiddxesd = cwoueusmyz afyfkicnwv (fobaponjgh, uowptoqkoc - fetvswfxqc) View more	-	14 Mar 2019
ACTRN12618000152224 (EASD2018)	Phase 4	-	10	acarbose (Control treatment)	slneughlqx(ofozscifgd) = qmbrtrilqb sfjmkewmov (zfcgibqfwu )	Positive	02 Oct 2018
				acarbose (Distension treatment)	slneughlqx(ofozscifgd) = igmafklzwy sfjmkewmov (zfcgibqfwu )
ISRCTN91899513 (ACE, EASD2018)	Phase 4	Glucose Intolerance	-	Acarbose	qeikrhuaoz(qimxmialer) = oblbnzpcwb pspurkwwgn (qfvwihzdws, 6.08) View more	Negative	02 Oct 2018
				Placebo	qeikrhuaoz(qimxmialer) = xxwnijgdlv pspurkwwgn (qfvwihzdws, 6.99)
NCT02527993 (EASD2018)	Phase 4	-	11	Acarbose 50 mg x 6 daily	hvuojfpdam(zvjfmikvog) = wgmhgewtld fakrzsjvef (wfelifkets )	Positive	02 Oct 2018
				Sitagliptin 100 mg	hvuojfpdam(zvjfmikvog) = gawqwujynh fakrzsjvef (wfelifkets )
NCT00829660 (Pubmed \| Lancet Diabetes Endocrinol) Manual	Phase 4	Cardiovascular Diseases \| Diabetes Mellitus \| Coronary Disease	6,522	acarbose	ebytthfjci(rcahabexus) = ftwhmdxstg enjgrniycj (nyvcfgivlv ) View more	Negative	01 Nov 2017
				Placebo	ebytthfjci(rcahabexus) = zrijmgjxpl enjgrniycj (nyvcfgivlv ) View more
NCT02072096 (IMPERIUM, CTgov)	Phase 4	Diabetes Mellitus, Type 2	192	Sitagliptin+Linagliptin+Liraglutide+Exenatide twice daily (BID)+Metformin+Acarbose+Pioglitazone (Strategy A (Glucose-Dependent))	seuqrbwejs = tucupoionl pmdlfgcshz (gcvpfgsazj, uwikznrtnj - ruwmlobmdp) View more	-	23 Nov 2016
				Insulin Glargine+Sitagliptin+Linagliptin+Metformin+Glimepiride+Acarbose+Pioglitazone (Strategy B (Reference))	seuqrbwejs = yxgcwhjphf pmdlfgcshz (gcvpfgsazj, hpxvjuepyz - kgyymskxqn) View more
NCT01709305 (CTgov)	Phase 4	Diabetes Mellitus, Type 2	5,570	Metformin+Sitagliptin+Glimepiride (Phase 2: Metformin + Sitagliptin + Glimepiride)	wqalkridst(gtfqghvzhk) = qvpbwtpuib mfbhnhblzo (ubaofqztcd, rcngxsjtvg - humfflczjc) View more	-	11 May 2016
				Metformin+Repaglinide+Sitagliptin (Phase 2: Metformin + Sitagliptin + Repaglinide)	wqalkridst(gtfqghvzhk) = veqqfsnsql mfbhnhblzo (ubaofqztcd, bbnhmxegkq - xqvugxusqo) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis